[go: up one dir, main page]

GB201223223D0 - Inflammatory bowel disease - Google Patents

Inflammatory bowel disease

Info

Publication number
GB201223223D0
GB201223223D0 GBGB1223223.7A GB201223223A GB201223223D0 GB 201223223 D0 GB201223223 D0 GB 201223223D0 GB 201223223 A GB201223223 A GB 201223223A GB 201223223 D0 GB201223223 D0 GB 201223223D0
Authority
GB
United Kingdom
Prior art keywords
inflammatory bowel
bowel disease
disease
inflammatory
bowel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1223223.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORINNOVA TECHNOLOGY TRANSFER AS
Original Assignee
NORINNOVA TECHNOLOGY TRANSFER AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORINNOVA TECHNOLOGY TRANSFER AS filed Critical NORINNOVA TECHNOLOGY TRANSFER AS
Priority to GBGB1223223.7A priority Critical patent/GB201223223D0/en
Publication of GB201223223D0 publication Critical patent/GB201223223D0/en
Priority to US14/653,750 priority patent/US10012654B2/en
Priority to ES13818771T priority patent/ES2915725T3/en
Priority to EP13818771.1A priority patent/EP2936162B1/en
Priority to PCT/GB2013/053418 priority patent/WO2014096873A1/en
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/555Interferons [IFN]
    • G01N2333/57IFN-gamma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1223223.7A 2012-12-21 2012-12-21 Inflammatory bowel disease Ceased GB201223223D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB1223223.7A GB201223223D0 (en) 2012-12-21 2012-12-21 Inflammatory bowel disease
US14/653,750 US10012654B2 (en) 2012-12-21 2013-12-23 Biomarkers in inflammatory bowel disease
ES13818771T ES2915725T3 (en) 2012-12-21 2013-12-23 Biomarkers in inflammatory bowel disease
EP13818771.1A EP2936162B1 (en) 2012-12-21 2013-12-23 Biomarkers in inflammatory bowel disease
PCT/GB2013/053418 WO2014096873A1 (en) 2012-12-21 2013-12-23 Biomarkers in inflammatory bowel disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1223223.7A GB201223223D0 (en) 2012-12-21 2012-12-21 Inflammatory bowel disease

Publications (1)

Publication Number Publication Date
GB201223223D0 true GB201223223D0 (en) 2013-02-06

Family

ID=47682445

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1223223.7A Ceased GB201223223D0 (en) 2012-12-21 2012-12-21 Inflammatory bowel disease

Country Status (5)

Country Link
US (1) US10012654B2 (en)
EP (1) EP2936162B1 (en)
ES (1) ES2915725T3 (en)
GB (1) GB201223223D0 (en)
WO (1) WO2014096873A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92982B1 (en) * 2016-02-25 2017-09-08 Univ Hamburg Eppendorf Uke IL-22BP as biomarker in anti-TNF-alpha-treatments
WO2017144603A1 (en) * 2016-02-25 2017-08-31 Universitätsklinikum Hamburg-Eppendorf Il-22bp as biomarker in anti-tnf-alpha-treatments
EP3963334A1 (en) * 2019-05-02 2022-03-09 University of Limerick A method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease
WO2022199682A1 (en) * 2021-03-26 2022-09-29 广州市妇女儿童医疗中心 Marker for diagnosis or early diagnosis of hirschsprung's disease and application thereof
GB202115242D0 (en) 2021-10-22 2021-12-08 Univ I Tromsoe Norges Arktiske Univ Methods of predicting stable remission in ulcerative colitis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0313864A (en) 1989-06-12 1991-01-22 Teijin Ltd Measuring method of tnf-alpha, kit and method of diagnosis
CA2190586A1 (en) 1994-05-17 1995-11-23 Scott E. Plevy Methods of screening for crohn's disease using tnf microsatellite alleles
WO1997039146A1 (en) 1996-04-12 1997-10-23 Cedars-Sinai Medical Center Methods of identifying and diagnosing inflammatory bowel disease
US6183951B1 (en) 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
GB0124315D0 (en) 2001-10-10 2001-11-28 Oxagen Ltd Inflammatory bowel disease
WO2005016954A2 (en) 2003-08-14 2005-02-24 Boston Medical Center Corporation Immunologic activity measure(s) for t “helper” on-associated conditions
ATE491953T1 (en) 2003-09-15 2011-01-15 Oklahoma Med Res Found METHOD OF USING CYTOKINT TESTING FOR THE DIAGNOSIS, TREATMENT AND ASSESSMENT OF ANKYLOID SPONDYLITIS
RU2258223C2 (en) 2003-10-31 2005-08-10 Лазебник Леонид Борисович Method for detecting indications for immunological correction of crohn's disease and inspecific ulcerous colitis
US20060205012A1 (en) 2004-12-09 2006-09-14 Meso Scale Technologies, Llc Diagnostic test
EA201000131A1 (en) 2007-08-02 2010-08-30 АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ DIAGNOSTIC, DETERMINATION OF THE STAGE AND MONITORING OF THE INFLAMMATORY DISEASE OF THE INTESTINE
AU2009320061A1 (en) 2008-11-03 2010-06-03 Merck Sharp & Dohme Corp. Inflammatory bowel disease biomarkers and related methods of treatment
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CA2750531A1 (en) 2009-01-23 2010-07-29 Drexel University Apparatus and methods for detecting inflammation using quantum dots
WO2010103350A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting the responsiveness to an anti-tnf alpha antibody treatment
US10041948B2 (en) 2010-10-12 2018-08-07 Mayo Foundation For Medical Education And Research Materials and methods for determining cancer risk
AU2012346861A1 (en) 2011-11-30 2014-06-19 AbbVie Deutschland GmbH & Co. KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor

Also Published As

Publication number Publication date
US20150323546A1 (en) 2015-11-12
WO2014096873A1 (en) 2014-06-26
US10012654B2 (en) 2018-07-03
ES2915725T3 (en) 2022-06-24
EP2936162B1 (en) 2022-04-20
EP2936162A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
GB201222205D0 (en) Early entry
GB201201727D0 (en) Indicating locations
GB201304182D0 (en) No details
EP2815691A4 (en) Endoscope
EP2692278A4 (en) Endoscope
EP2837320A4 (en) Endoscope
EP2835093A4 (en) Endoscope
IL237856A0 (en) Antigens associated with inflammatory bowel disease
EP2868252A4 (en) Endoscope
EP2856924A4 (en) Endoscope
GB201322435D0 (en) Early Entry
GB201214440D0 (en) Kidney disease biomarker
GB2500893B (en) Spirometer
GB2506845B (en) Modified tubular
GB201212069D0 (en) Predicting resistance to disease
GB201223223D0 (en) Inflammatory bowel disease
ZA201408522B (en) Line design
GB201309275D0 (en) Early entry
EP2543388A4 (en) Drug for inflammatory bowel disease
IL238769A0 (en) Enemas
GB201313844D0 (en) No details
GB201201805D0 (en) Speculum
EP2864414A4 (en) Pvc-acrylate blends
GB201308983D0 (en) Early entry
GB201020702D0 (en) Inflammatory disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)